Our early clinical program consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.Read more
We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.
In 2019, A1M Pharma has streamlined the strategy with full focus on clinical development of the drug candidate ROSgard.
The first clinical study of ROSgard and dosing of the first human subject started in April 2019. Approximately 35-40 healthy subjects will be recruited.
ROSgard is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.